ࡱ;   !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~Root Entry  \pCalc Ba=  !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|=@ 8X@"1Calibri1Arial1Arial1Arial1Calibri1Calibri General3._(\$* #,##0_);_(\$* \(#,##0\);_(\$* \-_);_(@_) #,##0\(#,##0_);[RED]\(#,##0\)!"($"#,##0_);[RED]"($"#,##0\) #,##0.00#\(#,##0.00_);[RED]\(#,##0.00\)                + ) , *   (  (    $      , (8 ( (8 (   (   ,  (    $    `rselected financial data!selected financial data-1borrowings currentVborrowings current-1"new products and first tim(productsmarketing and sales products-1 products-2t products-3l products-4 products-5intellectual propertyVintellectual property-1intellectual property-2"4!comparison of the years en$,comparison of the years en-1!6results by segments after$=results by segments after -1$rBresults by segments after -2$Hresults by segments after -3$@Oresults by segments after -4$.Tresults by segments after -5"vZebitda adjusted ebitda and$cebitda adjusted ebitda and-1lcontribution marginqcontribution margin-1"vcash flow for the years en"B{cash flow for the year end"debt financing and borrowiother term loans covenants"8contractual obligations an$Fcontractual obligations an-1rmajor shareholders!fees paid to the companys"Ҡconsolidated financial stalist of exhibits!"consolidated statement of$"consolidated statement of -1$<consolidated statement of -2$consolidated statement of -3$consolidated statement of -4"pnote 1 general company inf"i effect of the restatemen"&in thousands of united sta"ii effect of the restateme$in thousands of united sta-1!"disaggregation of revenue$*disaggregation of revenue -1$2in thousands of united sta-2 :note 8 segment reporting$VBin thousands of united sta-3$Jin thousands of united sta-4$ Rin thousands of united sta-5$6Zin thousands of united sta-6$pain thousands of united sta-7 igeographical information#nnote 9 finance expenses net"tnote 10 other expenses net"Nyincome tax recognized thro"}reconciliation of effectiv"*current tax assets and cur$@current tax assets and cur-1tnote 12 goodwill!.allocation of goodwill to!ڒnote 13 intangible assets#tnote 13 intangible assets-1"`note 14 property plant and$ note 14 property plant and-1"Nreconciliation of asset balease liabilities!jamounts recognized in the$ܿin thousands of united sta-8$Fin thousands of united sta-9znote 17 inventories net"note 18 trade and other renote 19 borrowingsnote 19 borrowings-12 other term loan3 lease liabilities4 factoring obligations5 put option agreementZ7 notes"reconciliation of liabilit%`in thousands of united sta-10%rin thousands of united sta-11F note 20 deferred tax<note 20 deferred tax-1pnote 20 deferred tax-2"note 21 trade and other pa"note 22 provisions and con""reconciliation of share ca"+procaps group sa and subsi$t.procaps group sa and subsi-1R1note 232 reserves5note 232 reserves-1"9note 24 earnings per share#:>note 25 warrant liabilities%|Bnote 25 warrant liabilities-1%TGnote 25 warrant liabilities-2"xKnote 261 reverse reorganiz$Nnote 261 reverse reorganiz-1$,Sprocaps group sa and subsi-2$Vprocaps group sa and subsi-3$8_procaps group sa and subsi-4$eprocaps group sa and subsi-5$jprocaps group sa and subsi-6$pprocaps group sa and subsi-7$Fwprocaps group sa and subsi-8"4~indicador bancario de refe2735 liquidity riskZ2735 liquidity risk-1$~procaps group sa and subsi-9outstanding activitiesvivax pharmaceuticals!loans to and from related$Rloans to and from related -1"ħtransactions with directorplist of subsidiariesprocaps group saprocaps group sa-1" exhibit 131ܼ exhibit 132T2*}||      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|3  @@   I SELECTED FINANCIAL DATAFor the Year ended December31,HConsolidated Statement of Profit or Loss and Other Comprehensive Income:202120202019Revenue Cost of sales Gross profitSales and marketing expensesAdministrative expensesFinance expenses, netOther expenses, net(Loss)/Income before taxIncome tax expenseLoss for the yearAs of December 31,As of January 1,<ConsolidatedStatementofFinancialPosition(atperiodend)2020 (asrestated)Assets:Non-current assets:"Property, plant and equipment, netRight-of-use assetsIntangible assetsDeferred tax assetsTotal non-current assetsCurrent assets:Cash Trade and other receivables, netInventories, netCurrent tax assetsTotal current assets Total assets/Liabilities and Stockholders Equity (Deficit):Equity (Deficit): Share premiumReservesAccumulated deficit$Accumulated other comprehensive lossTotal equity (deficit)Non-current liabilities: BorrowingsAmounts owed to related parties Warrant liabilitiesShares held in escrowDeferred tax liabilitiesOther liabilitiesTotal non-current liabilitiesCurrent liabilities:Trade and other payables, netCurrent tax liabilitiesTotal current liabilities4Total liabilities and stockholders equity (deficit)Borrowings (current)%Consolidated Statement of Cash Flows:2020 (asrestated)2019 (asrestated)*Cash flow provided by operating activities&Cash flow used in investing activities7Cash flow generated from (used in) financing activitiesNet increase in cashOther Financial DataContribution Margin (1)(2)Adjusted EBITDA (1)(3)(Revenue on a constant currency basis (4)-:Contribution Margin on a constant currency basis (1)(2)(4)6Adjusted EBITDA on a constant currency basis (1)(3)(4)+New Products and First Time Launch ProductsJNumber of product applications approved for the year ended December31Jurisdiction/Regulatory AgencyBolivia (AGEMED)Brazil (ANVISA)Colombia (INVIMA)Costa Rica (Health Ministry)Ecuador (ARSCA)El Salvador (DNM);Guatemala (Ministry of Public Health and Social Assistance)Honduras (ARSA)Nicaragua (Health Ministry)5Panama (National Directorate of Pharmacies and Drugs)Peru (DIGEMID)$Dominican Republic (Health Ministry)Venezuela (INHRR)TotalProductsEPercentage of NextGel s gross revenues for the year ended December31Softigel ProductCategoryGummiesFood/Supplements23%10%Advil Analgesics17%14% Isotretinoin Skin Care7%4% ProgesteroneHormonal5%6%Umbral1%Marketing and SalesCPercentage of NextGel Segment Sales for the year ended December31,Average Relationship Years (1)Selected ClientsBig Pharma (2)26%33%MBayer, Abbott, GlaxoSmithKline, P&G, Sanofi, Bausch + Lomb, Akorn and PerrigoRegional Pharma (3)52%50%XEurofarma, Biolab, Roemmers, PharmaScience, Liomont, Consilient Health and Hypera PharmaLarge Suppliers (4)22%Amway, Unilever and NestlPercentage of Farma Procaps gross revenues for the year ended December31Farma Procaps Product Gestavit Dha Feminine CareIsofaceCitragelMuvettDigestive HealthBetaduoPainFortzinkGrowth & Development3%Percentage of Clinical Specialties grossrevenues for the year ended December31Clinical Specialties ProductClenox Blood clot47%35% Tracurion AnestheticHypodermic needles HypodermicMerobac AntibioticTapectamSurgical masksMasks2%FNumber of Rx drug applications approved for the year ended December31ONumber of OTC drug applicationsapproved for the year ended December31Aruba (Health Ministry)NPercentage of Diabetrics gross revenues for the year ended December31Diabetrics ProductGlucoquick (1)Blood Glucose Monitor42%44% Predial LexRx oral anti-diabeticsGlucoquick AgujasInsulin Delivery Systems16%20%GMet15%LipoticIntellectual Property'Patents Granted as of December 31, 2021Product Type/TechnologyType of PatentJurisdiction of Registration Expiry DateUnigel TechnologyPatentColombia 18/07/2031Blefadex Composition Costa Rica 30/12/2034@Ribbon Printing (used to print capsules in a continuous process) Utility Model 30/07/2027Isoface Formulation 24/07/2023Ophthalmic containers Design PatentEcuador 07/08/2022Nasal Spray ContainerMexico?Degassing apparatus for dissolution media in analytical process 03/06/2026Cytogel Process 13/04/2025EuropeCanada#Electronic Dosage Dispensing System United States?05/25/2023 Extended under 35 U.S.C.154 (b) by 715 days@07/18/2031 Extended under 35 U.S.C.154 (b) by 97 daysA07/30/2027 Extended under 35 U.S.C.154 (b) by 694 daysKoreaJapanCynclor Project 29/08/2034%Laboratory-scale encapsulation deviceUtility Models 28/02/2029BrazilSpainGermany SwitzerlandFranceUnited KingdomItalyPolandPortugalSweden<Patent Applications Pending Approval as of December 31, 2021!Filing Date/ Publication Date 01/12/2016HME Technology&01/06/2015 09/09/2015 07/07/2016 19/08/201909/10/2015 11/15/2017 14/07/201611/23/2016 12/30/2016Peru06/27/2017 09/15/2017 El Salvador 29/06/2017Dominican Republic06/29/2017 06/15/2019 Guatemala 03/07/2017 05/07/201707/05/2017 11/09/201807/05/2017 09/05/201709/10/2015 03/13/201807/06/2017 11/15/2018 19/07/201707/27/2017 12/06/2017!Sweetener Composition for Gummies 07/21/2021 Face Mask 06/26/202008/02/2017 09/17/2018 13/02/2019 13/02/2020SGC Drying System^12/21/2016 12/21/2017 08/19/2018 03/28/2019 10/21/2019 06/06/2020 01/14/2021B05/25/2012 05/28/2013 06/12/2017 04/03/2020 11/11/2020 Vegan GummiesPCT 30/08/2019 06/25/2021Unigel Products (Diclofenac) 23/07/2020Ivermectin SGC Formula 30/09/2020Device for Gummies 11/09/2021Ivermectin Oral Solution 30/12/2020 19/03/202105/11/2015 22/06/2021 Poole Sample 07/28/2021&Clean Device for Soft gelatin capsules 08/13/2021 10/22/2021 09/23/2021EComparison of the years ended December 31, 2021 and December 31, 2020#For the year ended December 31,Increase/(Decrease)%Constant Currency Increase/(Decrease)$ Change% Change32021 - Constant Currency Adjustment (2).2021 - Constant Currency Basis (2)%Change1(in thousands of U.S. dollars except percentages)23.6%25.6%24.2%27.2%23.2%24.5%19.3%20.5%40.2%41.8%44.3%923.7% 10,366.0%21.3%865.5%Adjusted EBITDA (1)17.8%18.6%Contribution Margin (1)25.5%26.8%EComparison of the Years Ended December 31, 2020 and December 31, 2019"For the year ended December 31)Constant Currency Increase/(Decrease)32020 - Constant Currency Adjustment (2).2020 - Constant Currency Basis (2)$Change5(in thousands of U.S. dollars except percentages)2.1%11.9%(1.5)%8.2%4.8%14.8%(17.9)%(11.6)%(2.7)%6.9%Other expenses74.3%Income (loss) before tax(108.5)%60.6%(38.6)%43.1%58.0%24.6%37.8%Results by Segments After Inter-Segment Elimination, Excluding Corporate for the years ended December 31, 2021 and December 31,< 2020Reportable segments0Results for the year ended December 31, 2021NextGelProcaps ColombiaCANCASAND Diabetrics(in thousands of U.S. dollars)Contribution MarginConstant currency basis4Results for the year ended December 31, 2020 (1)Procaps ColombiaPComparison of results for the years ended December 31, 2021 and 2020 (1)Procaps Colombia DiabeticsResults by Segments After Inter-Segment Elimination Excluding Corporate for the years ended December 31, 2020 and December 31, 20190Results for the year ended December 31, 2020 (1)Constant currency basis (2)0Results for the year ended December 31, 2019 (1)MComparison of results for the years ended December 31, 2020 and 2019 (1)Constant currency basis (2)2EBITDA, Adjusted EBITDA and Adjusted EBITDA Margin#For the year ended December 31,865%Interest expense, net21%Depreciation and amortization(8)%EBITDA(91)%COVID-19 impact adjustments (1)(27)%'Business transformation initiatives (2)(100)%,Foreign currency translation adjustments (3)#Other finance costs adjustments (4)(65)%Transactions expenses (5)100%Listing expense (6)Adjusted EBITDA18%Constant Currency Adjustments*Adjusted EBITDA on Constant Currency Basis19%Adjusted EBITDA margin24.3%(1.2)%3Adjusted EBITDA margin (on Constant Currency Basis)24.1%"For the year ended December 31Increase / (Decrease)0.1%45.2% COVID-19 impact adjustments (1)(Business transformation initiatives (2)154.9%-Foreign currency translation adjustments (3)113.7%$Other finance costs adjustments (4)6.0%Colombia VAT tax reform (5)(100.0)%*Adjusted EBITDA on Constant Currency Basis18.2%7.3%3Adjusted EBITDA margin (on Constant Currency Basis)25.7% Gross ProfitSelling Expenses100.0%0Contribution Margin (on Constant Currency Basis)8Cash Flow for the years ended December 31, 2021 and 2020#For the Year Ended December 31,2020 (asrestated) (1)WCash Flow for the Year Ended December 31, 2020 Compared to Year Ended December 31, 20192020 (asrestated) (1)2019 (asrestated) (1)&Cash flow used in financing activitiesDebt Financing and Borrowings1For the Year Ended December31, 2021Syndicated LoanOther term loanLease liabilitiesFactoring obligationsPut option agreementsBank overdrafts Senior Notes"Total Interest bearing liabilitiesOther Term LoansCurrencyRange of InterestMaturity YearTOutstanding Balance for the year ended December31, 2021"(in thousands of U.S. dollars)COPIBR+ 2.25%-5.0% (Variable) 2022-2024DTF + 6.74%SOL5.00% - 10.01% (Fixed) 2021-2024REAIS9.84% - 13.08% (Fixed)USD'Libor + 2.99% / 6.5% - 8.7% (fixed)Libor + 4.49%10.00% - 30.00% CovenantsRange of InterestMaturity Year3Outstanding Balance as of December31, 2021+The Prudential Insurance Company of America 4.75%(Fixed)/Prudential Annuities Life Assurance Corporation1Healthspring Life & Health Insurance Company, Inc'CIGNA Health and Life Insurance Company'Contractual Obligations and CommitmentsAs of December 31, 2021(U.S. dollars in thousands)2022 2023-2024 2025-2026 After 2026Long-term debt obligations (1)Finance lease obligations (2)Trade and other payablesOther commitments (3)$Name and Address of Beneficial OwnerNumberPercentage (1)!Executive Officers and Directors:Ruben Minski (2)27.8%Jose Minski (3)15.9%Alejandro Weinstein (4)14.0%Kyle P.Bransfield (5)1.9%Daniel W.Fink (6)*BAll directors and executive officers as a group (five individuals)59.7%MAJOR SHAREHOLDERSFive Percent Holders:Sognatore Trust (2)Simphony Trust (3)Deseja Trust (4)&Hoche Partners Pharma Holding S.A. (5)14.1%%International Finance Corporation (6)8.4%.Fees Paid to the Companys Principal Accountant"For the Year Ended December 31 ( in thousands of U.S. dollars ) Audit feesAudit related feesTax feesAll other feesVConsolidated Financial Statements for the years ended December 31, 2021, 2020 and 2019IReport of Independent Registered Public Accounting Firm  PCAOB  ID 1183F-2|Consolidated Statement of Profit or Loss and Other Comprehensive Income for the years ended December 31, 2021, 2020 and 2019F-3gConsolidated Statement of Financial Position as of December 31, 2021 and 2020 and as of January 1, 2020F-5RConsolidated Statement of Changes in Equity as of December 31, 2021, 2020 and 2019F-6YConsolidated Statement of Cash Flows for the years ended December 31, 2021, 2020 and 2019F-7_Notes to Consolidated Financial Statements for the years ended December 31, 2021, 2020 and 2019F-8List of ExhibitsExhibit Number DescriptionAmended and Restated Articles of Association of Procaps Group, S.A., dated as of September 28, 2021 (incorporated by reference to Exhibit 1.1 to Procaps Group, S.A. s Form 20-F, File No. 001-40851, filed with the SEC on September 30, 2021).Specimen Ordinary Share Certificate of Procaps Group, S.A. (incorporated by reference to Exhibit 4.1 to Procaps Group, S.A. s Registration Statement on Form F-4/A filed August 17, 2021 (file no. 333-257222)).Specimen Warrant Certificate of Procaps Group, S.A. (incorporated by reference to Exhibit A of Exhibit 4.4 to Procaps Group, S.A. s Registration Statement on Form F-4/A filed August 17, 2021 (file no. 333-257222)).&Warrant Agreement, dated October 17, 2019, by and between Union Acquisition Corp. II and Continental Stock Transfer & Trust Company, as warrant agent (incorporated by reference to Exhibit 4.1 to Union Acquisition Corp. II s Form 8-K, File No. 001-39089, filed with the SEC on October 21, 2019).gAssignment, Assumption and Amendment Agreement with respect to the Warrant Agreement between Union Acquisition Corp. II, Procaps Group, S.A. and Continental Stock Transfer & Trust Company, dated as of September 29, 2021(incorporated by reference to Exhibit 2.5 to Procaps Group, S.A. s Form 20-F, File No. 001-40851, filed with the SEC on September 30, 2021).2.5*Description of Securities.4.1#9Business Combination Agreement, dated as of March 31, 2021, by and among Union Acquisition Corp. II, Crynssen Pharma Group Limited, Procaps Group, S.A. and OZLEM Limited (incorporated by reference to Exhibit 2.1 to Union Ac< quisition Corp. II s Form 8-K/A, File No. 001-39089, filed with the SEC on April 2, 2021).4.2#MAmendment No. 1 to Business Combination Agreement, dated as of September 29, 2021, by and among Union Acquisition Corp. II, Crynssen Pharma Group Limited, Procaps Group, S.A. and OZLEM Limited (incorporated by reference to Exhibit 4.2 to Procaps Group, S.A. s Form 20-F, File No. 001-40851, filed with the SEC on September 30, 2021).Form of Contribution and Exchange Agreement (incorporated by reference to Exhibit 10.1 to Union Acquisition Corp. II s Form 8-K/A, File No. 001-39089, filed with the SEC on April 2, 2021).Form of Subscription Agreement (incorporated by reference to Exhibit 10.2 to Union Acquisition Corp. II s Form 8-K/A, File No. 001-39089, filed with the SEC on April 2, 2021).Transaction Support Agreement, dated as of March 31, 2021 by and between Crynssen Pharma Group Limited, Procaps Group, S.A., Union Group International Holdings Limited, Union Acquisition Associates II, LLC, Union Acquisition Corp. II and investors in Union Acquisition Corp. II and Crynssen Pharma Group Limited (incorporated by reference to Exhibit 10.3 to Union Acquisition Corp. II s Form 8-K/A, File No. 001-39089, filed with the SEC on April 2, 2021).Registration Rights and Lock-Up Agreement, dated September 29, 2021, by and between Procaps Group, S.A., Union Group International Holdings Limited, Union Acquisition Associates II, LLC and the persons and entities listed on Exhibit A thereto (incorporated by reference to Exhibit 4.7 to Procaps Group, S.A. s Form 20-F, File No. 001-40851, filed with the SEC on September 30, 2021).kNomination Agreement, dated September 29, 2021, by and between Procaps Group, S.A., Union Group International Holdings Limited, Union Acquisition Associates II, LLC, and the persons and entities listed on Exhibit A thereto (incorporated by reference to Exhibit 4.8 to Procaps Group, S.A. s Form 20-F, File No. 001-40851, filed with the SEC on September 30, 2021).yShare Forfeiture Agreement, dated as of September 29, 2021, by and among Union Acquisition Corp. II, Crynssen Pharma Group Limited, Procaps Group, S.A., Union Acquisition Associates II, LLC and Union Group International Holdings Limited (incorporated by reference to Exhibit 4.9 to Procaps Group, S.A. s Form 20-F, File No. 001-40851, filed with the SEC on September 30, 2021).8.1*List of Subsidiaries.12.1*}Certification of Ruben Minski, Chief Executive Officer of Procaps, pursuant to Section 302 of the Sarbanes Oxley Act of 2002.12.2*Certification of Patricio Vargas Muoz, Chief Financial Officer of Procaps, pursuant to Section 302 of the Sarbanes Oxley Act of 2002.13.1**}Certification of Ruben Minski, Chief Executive Officer of Procaps, pursuant to Section 906 of the Sarbanes Oxley Act of 2002.13.2**Certification of Patricio Vargas Muoz, Chief Financial Officer of Procaps, pursuant to Section 906 of the Sarbanes Oxley Act of 2002. 101.INS***Inline XBRL Instance Document. 101.SCH***/Inline XBRL Taxonomy Extension Schema Document. 101.CAL***<Inline XBRL Taxonomy Extension Calculation Linkbase Document 101.DEF***<Inline XBRL Taxonomy Extension Definition Linkbase Document. 101.LAB***7Inline XBRL Taxonomy Extension Label Linkbase Document. 101.PRE***>Inline XBRL Taxonomy Extension Presentation Linkbase Document.XCover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)GConsolidated Statement of Profit or Loss and Other Comprehensive IncomeFor the year ended December 31Notes"Loss for the year attributable to:Owners of the CompanyNon-controlling interestsEarnings per share:QBasic, loss for the period attributable to ordinary equity holders of the Company!Other comprehensive income/(loss)6Items that will not be reclassified to profit or loss:.Remeasurement of net defined benefit liabilityYIncome tax relating to items that will not be reclassified subsequently to profit or loss Net of Tax?Items that will be reclassified subsequently to profit or loss:9Exchange differences on translation of foreign operationsWExchange difference from liquidated foreign transactions reclassified to profit or loss:Other comprehensive income/(loss) for the year, net of tax%Total comprehensive loss for the year?Total comprehensive income/(loss) for the year attributable to:,Consolidated Statement of Financial PositionAs of December 31As of January 1As Restated*AssetsNon-current assetsGoodwillInvestments in joint venturesOther financial assets Other assetsCurrent assetsAmounts owed by related partiesOther current assets.Liabilities and Stockholders Equity (Deficit)Equity (Deficit) Share capital6Equity (deficit) attributable to owners of the companyNon-controlling interestNon-Current liabilitiesCurrent liabilities Provisions+Consolidated Statement of Changes in Equity+Attributable to equity holders of the GroupIssuedCapitalShare premium Reserves 1Accumulated deficit"Other Comprehensive IncomeNon-controlling interestTotal equity (deficit)Balance as of January 1, 2019Transfer reserves$ Other comprehensive incomePut option issued to HocheOtherBalance as of December 31, 2019Balance as of December 31, 2020Loss for the year 2$Termination of put option agreementsSubtotalWCapital restructuring of Crynssen Pharma Group Limited (at exchange ratio of 1:33.4448)Subtotal - restructured)Acquisition of Union Acquisition Corp. IIRedemption of redeemable sharesBalance as of December 31, 2021$Consolidated Statement of Cash FlowsOperating activitiesJAdjustments to reconcile net loss < with net cash from operating activities:-Depreciation of property, plant and equipment#Depreciation of right-of-use assetsAmortization of intangiblesFinance expenses4IFRS 2 Share-based payment expense (listing expense)!Share of result of joint ventures8Net (gain)/loss on sale of property, plant and equipment2Net (gain)/loss on sale or disposal of intangiblesInventory provisionReversed provision for bad debtECash flow from operating activities before changes in working capital8(Increase)/decrease in operating assets and liabilities:Trade and other receivables InventoriesCash generated from operations Interest paidDividends receivedIncome tax paidInvesting activities,Acquisition of property, plant and equipment3Proceeds from sale of property, plant and equipmentAcquisition of intangibles'Proceeds from sale of intangible assetsAdvances to related partiesProceeds from related partiesFinancing activitiesProceeds from borrowingsPayments on borrowingsAdvances from related partiesPayments to related partiesInterest paid on borrowingsPayment of lease liabilitiesRedeemed sharesCash obtained in acquisition$Cash at beginning of the year/period$Effect of exchange rate fluctuationsCash at end of the year/period.Non-cash financing and investing activities 1#Note 1. General Company InformationPlace ofOwnership interests held by:business/country The GroupName of entityof incorporationPrincipal activities Procaps S.A. %\Manufacturing and distribution of prescription and over-the-counter pharmaceutical products.C.I. Procaps S.A.@Procaps S.A. de C.V (previously Laboratorios Lopez S.A. de C.V.)Softcaps - ColbrasDiabetrics Healthcare S.A.S.7Diabetes solutions and chronic disease management tool.<I. Effect of the restatement on annual financial informationAs of December 31, 2020As of January 1, 2020Balance Sheet, restatedAs reportedRestatement AdjustmentsAs restatedFRestatement AdjustmentsCurrent liabilities!Trade and other payables, net@(In thousands of United States Dollars, unless otherwise stated)7For the twelve month period ending December 31, 20206For the twelve month period ending December 31, 2019As reportedRestatement Adjustments 1Other Reclassifications 2As restated As reported;(Increase)/decrease in operating assets and liabilities:4Cash flow provided by (used in) operating activitiesInvesting activities:4Cash flow provided by (used in) investing activitiesFinancing activities:7Cash Flow generated from (used in) financing activitieskII. Effect of the restatement on unaudited condensed consolidated interim financial information (Unaudited)As of June 30, 2021Balance Sheet, restatedRestatement Adjustments As restated1For the six month period ending June 30, 20211For the six month period ending June 30, 2020Restatement Adjustments (1)Restatement Adjustments (2)7Disaggregation of revenue from contracts with customers Year 2021 CorporateSegment revenueIntra-segment revenue%Revenue from contracts with customersTiming of revenue recognition$Goods transferred at a point in timeServices transferred over time+Total revenue from contracts with customers Year 2020 Year 2019Note 8. Segment reporting Year 2021Inter- segment eliminationsExternalInter- segment eliminationsContribution margin 1Inter- segment eliminations!Inter- segment eliminationsContribution margin 1Geographical information South AmericaCentral America North AmericaNote 9. Finance expenses, netBanking expenses Bank feesOther financial expenses*Net fair value gain of warrant liabilities,Net fair value gain of shares held in escrowInterest expenseNote 10. Other expenses, net"Currency exchange rate differences(Economic emergency contribution expenses.Fines, surcharges, penalties and taxes assumed DonationsListing expense (a),Income tax recognized through profit or loss Current yearCurrent tax expense1Origination and reversal of temporary differencesDeferred tax expenseTotal tax expense$Reconciliation of effective tax rateProfit/ (loss) before taxIncome tax (benefit)/expenseLTax effect of expenses that are not deductible in determining taxable profit>Tax effect of income not taxable in determining taxable profitNEffect of different tax rates of subsidiaries operating in other jurisdictionsOthers - Includes exchange effects for reversal rates of long-term temporary differences, income taxed at differential rates, effects of change in deferred tax rate and tax discountsATax effect of utilization of tax losses not previously recognizedTax expense for the year/Current tax assets and current tax liabilities:Income Tax AdvanceIncome Tax WithholdingSurplus in Private LiquidationOther Tax AssetsIncome Tax PayableOther Tax LiabilitiesTax Losses not utilizedTax Credits not utilizedNote 12. Goodwill'Balance at beginning of the year/period'Effect of movements in foreign exchange!Balance at end of the year/period/Allocation of goodwill to cash generating unitsBiokemical S.A. de C.V. Rymco S.A.Note 13. Intangible assetsCost'Trademarks and sanitary records*Licenses, customersand agreementsProduct developmentBalance as of January 1, 2020 Additions$Additions from internal developmentsDerecognition of assetsForeign currency exchangeReclassificationsReclassifications and othersAccumulated amortizationAmortization expenseAs of December 31, 2020Net book value+Note 14. Property, plant and equipment, netLand and buildings;Machineryand equipment, furniture and fixturesProjects in progressOther 1 Disposals2Effect of exchange differences in foreign currency#Reclassification between categoriesAccumulated depreciationDepreciation expense!Reconciliation of asset balances:Land and BuildingsEquipment and MachineryVehicles ComputersAddition to right-of-use asset Depreciation+Effect of changes in foreign exchange ratesDerecognition of contractsLease Liabilities Non-currentCurrentBAmounts recognized in the Consolidated Statement of Profit or Loss"For the year ended December 31Interest on lease liabilities$Expense relating to low value assets%Expense relating to short term leasesAs of December31, 2021As of December31, 2020Non-current liabilitiesEquityProfit/(loss) for the yearTotal comprehensive incomeNet assets of Promedical S.A.AProportion of the Company s ownership interest in Promedical S.A.Other adjustments<Carrying amount of the Company s interest in Promedical S.A.Note 17. Inventories, netRaw materials and suppliesProducts in process!Finished products and merchandiseInventory in transitLess: Provision)Note 18. Trade and other receivables, net!For the year ended December 31&Trade receivables, net of discounts 1Impairment of trade receivablesOther receivables2Trade receivables, net of discounts and impairmentNote 19. BorrowingsRestated&Unsecured borrowings at amortized costSyndicated term loan (1)Other term loan (2)Lease liabilities (3)Factoring obligations (4)Put option agreement (5)Bank overdrafts (6) Notes (7) Non- CurrentRange of InterestMaturity YearSyndicated term loanIBR+ 5.3% (Variable)Libor+ 4.8% (Variable)Amortized costN/ATotal Syndicated term loan2. Other term loanRangeofInterest Maturity YearIBR+ 2.25%-5.0% (Variable) DTF + 6.74% 24% (Fixed)5.00% - 10.01% (Fixed)9.84% - 13.08% (Fixed) Libor + 4.49%'Libor + 2.99% / 6.5% - 8.7% (fixed)10.00% -30.00%Total Other term l<]oans3. Lease liabilitiesMaturity Year,DTF +5.18% - DTF 10.11% T.A. IBR + 7.50%&DTF+ 4.54% + DTF 8.5%T.A. + DTF+10.42%DTF+17% / (DTF+13.72%) 14.70% E.A. 9.28% T.A. 9.75% N.M.8.29% - 21.48% E.A.Reales 1.68% (Fixed)Total Lease liabilities4. Factoring obligationsPortfolio factoringDTF+8% / 24.6% (Fixed) 12% (Fixed)DTF+8%/ 24.6%(Fixed)Total Factoring5. Put option agreementMaturity YearIFC12%HocheTotal Put option7. Notes 4.75% (Fixed)Total Senior Notes?Reconciliation of liabilities arising from financing activitiesJanuary 1, 2021Paymentcash flowsNew liabilities 1Other changes 2December31, 2021Put option agreement+Total liabilities from financing activitiesJanuary 1, 2020Payment cash flowsNew liabilities 1Other changes 2December31, 2020January 1, 2019New liabilitiesOther changesDecember31, 2019Note 20. Deferred tax"Net deferred tax asset (liability)Property, plant and equipment Intangibles'Borrowings and Trade and other payables Provisions and Other liabilitiesOthers(Total net deferred tax asset (liability)Deferred Tax AssetDeferred Tax Liability"Net Deferred Tax Asset (Liability)Balance as on January 1Recognized in Profit and Loss+Recognized in Other Comprehensive Income 1 Others 2Balance as of December 31&Note 21. Trade and other payables, netTrade payablesOther payablesTrade current accountsInterest payable&Withholdings and payroll contributionsTotal other payablesTotal accounts payable%Note 22. Provisions and contingencies ContingenciesBalance as of January 1Provisions madeProvisions used1Reconciliation of share capital and share premium%Ordinary authorized and issued sharesNumber of sharesShare capital amount'As of January 1, 2019 pre-restructuring!Issuance of put option with Hoche@Capital restructuring of Crynssen (1:33.4448 exchange ratio) (b)$As of December 31, 2019 restructured'As of January 1, 2020 pre-restructuring$As of December 31, 2020 restructured'As of January 1, 2021 pre-restructuring(Termination of put option agreements (a)-Acquisition of Union Acquisition Corp. II (c)Escrowed shares (d)#Redemption of redeemable shares (e)Procaps Group S.A. and subsidiaries (The Group) Notes to Consolidated Financial Statements For the years ended December 31, 2021, 2020 and 2019 (In thousands of United States Dollars, unless otherwise stated)Aggregate value Public sharesFounder shares PIPE SharesShare premiumSPAC net assetsTransactions costs"IFRS 2 Share-based payment expenseShare Capital issuedNote 23.2. ReservesLegal 1Working Capital 2Increase in legal reserves$Increase in working capital reservesNote 24. Earnings Per ShareNet loss of the year0Number of ordinary shares issued at December 31*0Weighted average basic number of ordinary shares%Assumed exercise of share equivalents)Weighted average diluted number of shares,Basic and diluted loss per share in the yearNote 25. Warrant LiabilitiesPublic warrantsPrivate warrants 1As of January 1Acquired public warrantsWarrants exercisedFair value remeasurementAcquired private warrants!Note 26.1. Reverse reorganization(Amount in thousands)Cash held in trustCash and cash equivalentsRedemption liabilityWarrants liability0Total SPAC identifiable net assets at fair valueAfter Redemption%Step 1 - Deemed cost of shares issuedFair value of OpCoFEquity interest in Holdco issued to SPAC shareholders & PIPE investors1Equity interest in Holdco of Selling shareholders81%Deemed costs of shares issued**SPAC identifiable net assets at fair valueDeemed cost of shares issued1Step 2 - Dilutive impact of shares held in escrowdDilutive effect of 945,036 shares held in escrow at a weighted average fair value per share of $9.08!Step 3 - IFRS 2  listing expense Property, Plant and EquipmentRight of Use AssetsFVTPL 1Amortized cost 2FVTPLAmortized cost 2+Financial assets not measured at fair value1Total financial assets not measured at fair value,Financial liabilities measured at fair value2Total financial liabilities measured at fair value0Financial liabilities not measured at fair value6Total financial liabilities not measured at fair valueDecember 31, 2021Current (not past due)1-30 days past due31-60 days past due61-90 days past due91-120 days past due#Morethan 120days pastdueWeighted-average loss rate0.60%2.11%2.35%3.38%3.26%67.43%14.67%Gross carrying amountImpairment loss allowanceDecember 31, 2020#Morethan 120 days past due0.53%2.59%2.81%5.82%14.78%59.77%9.60%December 31, 20190.68%1.98%2.49%4.36%5.10%80.12%10.99% LiabilitiesCrdoba QuetzalesSolesDOPColones(+10% Impact to profit or loss before tax(-10% Impact to profit or loss before tax Indicador bancario de referenciaCarrying amount+1%-1%Carrying amountDTF/IBRLibor27.3.5. Liquidity riskContractual cash flowsLess than 1 year 1-2 years 2-3 years 3-5 yearsMore than 5 years$Non-derivative financial liabilitiesTotal assets 1Total liabilities 2Liabilities to assets ratioOutstanding activitiesSale of finished products$Revenue from services and consulting-Purchases of raw materials and other servicesVivax PharmaceuticalsLoans owed to related parties!Loans to and from related partiesLoans to related partiesLoans advancedLoan repayments receivedLoans from related partiesLoan repaymentsInterest accruedBTransactions with directors and executive board management membersShort-term employee benefitsConsulting feesList of Subsidiaries Subsidiary JurisdictionCrynssen Pharma Group LimitedMaltaUnion Acquisition Corp. IICayman IslandsFuntrition S.A.S.Crynssen Pharma S.A.S.Procaps S.A. de C.V.Biokemical, S.A. de C.V.2Corporacin Distribuidora Internacional S.A. de CVCDI Sociedad Annima Nicaragua#Pharmarketing Salvador S.A. de C.V.Pharmarketing S.A.PanamaPharmarketing Dominicana S.R.L.Pharmarketing Costa Rica S.A.Unimed del Per S.A.Roddome Pharmaceutical S.A."Colbras Industria E Comercio Ltda.Rymco Medical S.A.S. Horslig GmbHPharminter GmbHSofgen Pharmaceuticals LLCPromedical S.A.Bolivia Unimed Farmaceutica Holding S.L.Allophane Holdings S.L.Hadwen International LimitedBritish Virgin IslandsAvisol Investments LimitedDBM International CV NetherlandsSofgen Pharma LLCIndustrias Kadima S.A.S.Inversiones Jades S.A.S.Inversiones Ganeden S.A.S.Inversiones Henia S.A.S.Inversiones Crynseen S.A.S.>Colombiana de Suministros Mdicos Hospitalarios  Colmed Ltda-Pharmayect S.A.Procaps Paraguay S.A.ParaguayFuntrition LLCProcaps Group SABy:/s/ Ruben MinskiName: Ruben MinskiTitle:Chief Executive Officer/s/ Patricio Vargas MuozPatricio Vargas MuozChief Financial Officer Exhibit 13.1Date:April 29, 2022 Exhibit 13.2J" ,9G Wx ۜYxcc   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} H} }  } }  }  } }  , , , , , , , , , , , , ,         ~ :~ .;~   ~ `~ r~  P ~ c~ J ~  #  ~ >~ ~    ~ ~ k~ ~R  ~ R3~ ~ f`  ~ -~ r~ ں  ~ *~ F ~ d ~ )~ O~  ~  ~ \~  .:  PH0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} <} }  } }  }  } } (  @ , , , , , , , , , , , , , , ,,, , , , , ,, , , , , , , ,                     ~ n~ J~   ~ s~ ~  bV ~ n~ ~  j ~ nn~ &T~  ^ ~  ~ ҫ ~ ~  ~ f~ B~  ~ &+~ ~ J ~ ~ r~  ~  Y~ ~  h  ~ .1~ E ~   !~ 4~ ~   " # $~ 6 ~ 2R~  2R %~ ~ fo~  & &~ ~ B~  zX '~ M~ n~  ތ (~ ~ t~  V ) *~  ~ j~  : + ,~   , -~ "i ,  , .~ 7 ,  , /~ ^~ *'~  w 0~ *~ V;~  VO 1~ ~ ~  :V ,! ," ,# ,$ ,% ,& ,' , 2 !*~ !Z~ !r~ !  "3~ "6~ "~ " b #+~ # ~ #.~ #  $4~ $~ $ƒ~ $ u %0~ %p~ %~ % f &5~ &x ~ &2~ & v* '6~ '4~ '~ ' j     PH 0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} 7} }  } }  }  } }  , , @ , , , , 7  8  9  :  ;~ F~ "T~  * <~ ~ ~  nC =~ ~ ~  n" >~ r_~ "~  Ґ2  PH0 0(   >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} :} }  } }  }  } }  , , , , , , , , 7  ?      @~ BQ ~ Vm~  b A~ z~ .*~   B~ i~ F0  C D~ Bj ~ 6  C E~  ~ > C2  PH@0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} ;} }  } }  }  } }  , @ , , , , , , , , , , , , , , , F G H      I~ ~ ~  & J~ ~   , K~ v~ *~  R L~ ~ ~   M~ "~ :~  N~ R~ :~ 2 O~ ~ *~ 6 P~ V~ B~ . Q~ ~ ~  R~ "~ ~  2 S~ 6~  ~  * T~ 6~ ~   U~ ~ ~   V~ ~ ~~  *  PHP0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} } } } } } } }  , , , , , , , , W X Y Z    [ \ ]  ^ _ ` a  b c d e  f g h i  j k ` l e"  PH`0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} } } } } }  } } } X}  , @ , , , , m n  o Z      p   q r s t~  J  u v w x~  "  y z { a~  &  |"PHp0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} } } } } } } }  , @ , , , , , , , W } ~ Z ~  ~      e  e  d e  j   j  e   j  i   i f    i PH 0(   >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} } }  } } } } }   @ , , , , , , ,   Z ~  ~           ^  j   ^  i   j  f   i  j     a  PH$0(  $>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} ;} }  } }  }  } }   , , , , , , , , , , , , , , , ,  H      I~ ~ ~   J ,~   , K~ .~ &~  F L ,~ ~   M~ ~ .~   N~ ~ .~   O~ F~ ~ 2 P~ ~ .~  Q~  ~ ~  R ,~ ~ 2 S~  ~ ~ & T~ *~ ~   U~ ~ ~   V~ ~ &~  Z"  PH(0(  (>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} ;} }  } }  }  } }   @ , , , , , , , , , , , ,  H      ~  ,  , I~  ,~   K~  ~ ~        !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~ M ,~ ~   N~  ~ ~   O~ ~  ~   P~ ~ ~  Q~ ~ ~  S ,~ ~  T~ ~ ~  V~ b~ N~ ^"  PH,0(  ,>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} } } } } } } }  , @ , , , , , , W   Z           a  e        ^     f "  PH00(  0>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} @} } } } } } A} ,, @,,,,, , , , , ,,,, @, @, @,,,,,,,,,,                                                                                                                   ,!,",#,$,%,&,',(,),*,+,     ! ! ! ! " " " " # # # # $ $ $ $ % % % % & & & & ' ' ' ' ( ( ( ( ) ) ) ) * * * * + + + +PH40(  4>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} #} } } } } } ^}   @ @, @, @, @  @ ,  @ , ,, @ @ @ @, @,, @,,, @ @,,,                                                                                                                          PH80(  8>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} &} }  } }  } } }  ,,,, @,,, ,                                         PH<0(  <>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} } }  } }  }  } } }  } }  } }  } }  } } }  , @ @ , , , , , , , ,,,, , ,                  @ ~ :~ .;~    ~ g~ i~ . ! ~ `~ r~   "~ ~ ~  # ~ c~ J ~   $~ %~ ʈ~  %  ~ >~ ~ 2. &~ >~ z~ n! '  ~ ~ k~  (~ ~ ~  )  ~ R3~ ~  *  ~ -~ r~ V +  ~ *~ F ~   , ~ )~ O~  ^ - ~ ~ \~  B{ . /~ z~ .*~  N 0~  ~  ~ V 1 2~ BQ ~ Vm~   3~ ~ Bj ~  4r  PH@0(  @>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} } }  } }  }  } } } } }  } }  } }  } } }  , @ @ @ , , , , , , ,,,, , , 5 6    6 7       8 9 :   ;> ~ .;~ ~  Nh <~ ~ F0~ f] = ~ r~ P~  v! >~ B(~ ^~ I ? ~ J ~ # ~  ‰ @~ Z~  ~  A  ~ ~ ~ 6 B~ :~ Fl~ n C  ~ k~ ~R~ j D~ ~ ~ n E  ~ ~ f`~ :L 4 F~ r~ ں~  G H~ F ~ d~  . I ~ O~ ~  n J ~ \~ .~  f K /~ .*~ ~  . L~ ~ >~ > M 2~ Vm~ b~  v N~ ~ 6~ @ Or  PHD0(  D>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} 0} }  } }  }  } } }  } }  } ,, @,,,, , , , , P Q( R S T  U  V W X( ~ _~ z ~  ~ K~ ^ ~ ~ 6~  6~ ~ R Y~ jM~ F+~  !~ S~ k Z ~ ~  ~ *'~ .L~ f ~ ~~ ~ v~ ~  Y~ T~ ,~ $~ FS~ .lB PH H0(  H>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} 4} }  } }  }  } } }  } }  } , @,,,, Q( [ S \  U  V W X( ~ w~ >~  ~ rZ~ d ~ ~ ~  ~ ~  Y~ ~ ޓ~  ~ Z~ U: PH0L0(  L>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} P} }  } }  }  } } }  } }  }  , @,,,,, , , , Q( ] S ^  U  V _ X( ~ ~ w~  2S~ ~ J\ ~ r~ ~  B~ ~ 6* Y~ p~ j~  /~ ƹ~ F Z ~ ~ Ο~ v^~ ~ Rb ~ ڂ~ v#~ G~ ~ , Y~ ^w~  ~ V2~ ~ r: PH@P0(  P>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} 0} }  } }  }  } } }  } }  } ,,,,,,, , , , , ` Q( a S ^  U  V W X( ~ w~ >~  ~ rZ~ d ~ ~ ~  ~ ~  Y~ ~ ޓ~  ~ Z~ U b ~ V~ ~ ~ a~ ֐ ~ ~ h~ v~ ^~ j Y~ ><~ ~ ~ ~ r`B PHPT0(  T>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} 0} }  } }  }  } } }  } }  } ,,,,,, Q( c S ^  U  V W X( ~ &~ T~  >~ q~ R[ ~ b~ ~  ~ 2~  Y~ rd~ H~   ~ ڢ~ K: PH`X0(  X>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} M} }  } }  }  } } }  } }  }  , @,,,, @ , , , Q( d S ^  U  V W X( ~ ʇ~ ~~  z~ ~~  ~ Fq~ V~  ~ ~ ^ Y~ 6x~ .K~  ~ ~~  !e ~ f~ ~ v~ ~ 5 ~ ~ VY~ z~ 2~  Y~ ~ Ҭ~ ~ "~ : PHp\0(  \>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} 3} }  } }  }  } } } } , @,,,,, , , , , ,,,,,,,,, f g            ~ ~ \~  B{ h i~ ~ fS~  Ny  ~ &~ ~  % j k~ ~ v~  l m~ f~ b~  n o~ 2;~ P~ B p q ,~ ~  r s~ >~ =~   t~  ~ 2~   u v~  ,~   w x~  ,~   w y~ z~ .*~  N z {~  ,~   w |~ " ~ .*~  "V } ~  3   B  PH`0(  `>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} 3} }  } }  }  } } } }  @,,,,,,, , , , , ,,, @, @             ~ \~ .~  f K i~ fS~ ~  ʳ 4 ~ ~ m~  B J k~ v~ J~  .  m~ b~ ~  "]  ~ P ,~ P w ~ ~  ~ ^  ~ =~ ~ z  ~ 2~ n~    ,~ ~R~   y~ .*~ ~  . L {~  ,~   w ~ >~ ~  > M ~ 3    :  PHd0(  d>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} 0} }  } }  }  } } } }  , @,,,,, , , Y             ~ c~ J ~   $ ~ >~ ~  2. & Y~ BQ ~ Vm~   3 {~  ,~   ~ Bj ~ Vm~  4B  PHh0(  h>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} 0} }  } }  }  } } } }   @,,,,,,,             ~ J ~ # ~  ‰ @ ~ ~ ~  6 B Y~ Vm~ b~  v N {~  ,~   w ~ 6~ b~  @ O:  PHl0(  l>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} 7} }  } }  }  } }  , @ , , , , , ,           X ;~ F~ "T~   <~ ~ ~   =~ ~ ~   >~ r_~ "~ R:   PHp0(  p>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} *} }  } }  }  } }  , @ @ , , , , ,           X ;~ "T~ *~  *) <~ ~ nC~   ~ ~ n"~  d >~ "~ Ґ~ R?:   PHt0(  t>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} "} }  }  , @,,,,, , , , ,   X ~  ~ && ~  ~ ƥ  , ~  ~ f ~ vPHx0(  x>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} } } '} }  }  , @ @ @ @ @ @ @ @ @ ,              ~     ~ ~  J1    ~  ]    ~      ~ F   ~ ~     ~ ~   V ~ #&& # j       PH|0(  |>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} 1} } } }  } } }  , @,,,,,           ~  ~  j    ~  ~      ~  ~  ^    ~  ~  e  V~  f B      PH0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} } }  } }  }  } } }  } }  }  ,,,,,,, , ,  (        V ~ d~ ~  ~  ~ Nq ~ ~ s~  VS~ ~ o ~ 6 ,  , ,~ 6 +~  ,  , ,~  ~ 8~  , ,~ Q V~  ~ ~ B~ # ~ : PH0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} B} }  } } }  ,,,,,,,,       Zx  J3H  2  r  ~   ~ " "PH 0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} &} }  } } }  ,,,,,,, ,        Zx  J3H  J3H  2   ._C *PH00(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} } }  } }  }  , @,,,,, , ,     $$$$$$ ~ I~   C C  C C  C C V~ I~  *PH@0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} d} } }  ,,,,,,,              PHP0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} } } d} , @,,,,, , , , , ,,,,,,,,,,,,,,,,,   %? ~ % %@ %ffffff@ ~ %          ~ %   %@  ~ %  %ffffff@ ~ %[ ~ %                  ! " # $ % & '~  ( PH`0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} Q} }  } }  } } } } } ,,,,,, , , , , ,,,,,,,, ) * +       ~ ~ :~ .; ~    ~ `~  r~  P ~ c~  J ~  #  ~ >~ ~   ~ ~ k~ ~R  ~ &~ R3~ ~ f`  ~ *~ -~ r~ ں  ~ *~ F ~ d ~ .~ )~  O~   ~ &&~ &\ &~  &. & , -~ ~  \~  B . ,  ,~   / 0~ b~ 'g~  '~  'Z        PHp0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} Y} } } }  }  } } }  } ,,,,,, , , , , ,,,,,,, ) * +       ~ &&~  &\ &~  &.& 1 2 3~ ~ F~  4~ ~ B~ V 5~ &~ ~ > 6 7~ &~ ~ " 8~ F  , , 9~ ~  ~ ^ :~ &&~  &VR &~  && ; -~ f~  K~ V .~ .~  ~ 6Z       PH0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} 6} }  } }  } } } } } 6, @, @,,, , , , , ,,,,,,,,,,,,,,,,,, < =  >        +  ?   ?  @     A     ~ :~ n~  J~   ~ >~ s~ ~ bV B~ 2~ Nj~ >k~ m ~ 6~ n~ ~ j C~ B~ .&~ r&~  D~ ~  ~  ~ R~ nn~  &T~  ^ E~ F~  :~  0 ~  ~ ҫ  ~  ~   F ~ f~  B~   ~ J~ &+~  ~  J ~ F~ ~  r~   G~ v~ ~   (~  ! ~ .~  Y~  ~  h H~ %(~ >[~  ~    ~ .1~ E  ~     !~ 4~  ~    I J K~ ^~ ~  F~  F $~ ^~ 6 ~  2R~  2R %~ ^~ ~  fo~  & ,!,",#,$,%,&,',(,),*,+,,,-,.,/,0,1,2,3,4,5, &~ ~ B~ zX !'~ !M~ ! n~ ! ތ "L~ "&"&~ "&h" &~ " &" & #M~ #R~ # & ~ # j $(~ $&$&~ $&t$ &~ $ &V$ & %N &*~ &N~ & ~ & j~ & : '+~ 'v ',~ '  ' , (-~ (f~ ("i ( , ( , ).~ )7 */~ *R~ *^~ * *'~ * w +0~ +*~ + V;~ + VO ,1~ ,,~ ,, ~ , :V,  -O .*~ .N~ .Z~ . r~ .  /3~ /V~ /6~ / ~ / b 0+~ 0v~ 0 ~ 0 .~ 0  14~ 1.~ 1~ 1 ƒ~ 1 u 2P~ 2Z~ 2~ 2 ~ 2 # 30~ 3p~ 3 ~ 3 f 45~ 4x 4~ 424 ~ 4 v*4  56~ 545~ 55 ~ 5 5 :'                """" "" $$$$ $$ ,,,, ,, 4444 44 5555 55 PH0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} W} }  } }  }  } } }  } }  } }  } }  } }  }  , , @ , , , , , , , , , , , , , , , , , , , , , , , , , , Q R@ S T  U  V W V X Y Z~ &~ ^U~   ~ &u&~ &&~ &.&~ 6~ &*5&  , ,  ,~ B ,~ B~ ~ . [ \ \~   ~ &f& \ \ \ \ ] , ,  , ,~  ~  ~ J~ ^ M , , , ,~ J~ J ,~ J ^~ &R &~ & & \ ~ &^ & \ ~ & & \ ~ & & _ , , ,~  ,~  ,~  `~ F ~ 2R ~ & ~ &zX &~ &ތ &~ & &~ j ~ &V &  , , ,~ \ ,~ \ ,~ \ [ , ,~  B~ P , , , , ] , ,  , ,~ ~ ~ ~  M , ,  , ,~ ~  ,~  _ , ,  ,~ F ,~ F ,~ F a~ F~ 2R~  fo ~ &B&~ &n&~ &h&~ & ~ &t& b , ,  ,~ ~ F~ J ,~ J [ , ,~  ,~ r , , , , ] , ,  , ,~ ~ ~ .~ J M , ,  , ,~ .~ . ,~ . c~ ~ -  , , ,~ .; ,~ .; d~ b-~ B~  ~ ~ M~ BG~ R~ 8 e~ ~ 6  , , , , , , f~ .~ v~  ~ ~ M~ BG~ R~ 8 g~ *~ J  , , ,~ r ,~ r .~ .~   , , ,~  ,~  h~ N~ A  , , ,~ @ ,~ @ i~ ~ 6 ~   ~ &&~ &M&~ &&~ &R&~ &&:                   PH0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} J} }  } }  }  } } }  } H,,, @,,, , , , , ,,,,,,,,,,,,,,,,,, j  *       +   ?  ? k      ~ &&~  &\ &~ &.& l m~ :~ ^~ 2\~ i n~ >~ A~ G~ 6P o~ 6~ BK~ n]~ BG ~ .~ &~ ~ m p~ &~ ~ fS~  q~ *~   , , r~ ~  j~ B s~ :~ ~  ~  t~ 6 ,~  ~ . u~ F~ >T~  B~   v~ J~ :~  ~ J P~ Z ,~   ~ 2 w~ .1~  Za~  x y~ ޳~  ~ Vi G~ ~  n~  z~ "~  ~ > ~ ~  b~  H~ ~  vi~ zf ~ ~  N~   +~ "~  *~  4~  ~  .u~ v ,!,",#,$,&,',(,*,,,-,.,/,0,1,2,4,6,7,8,9 ,:,;,<,=,>, 0~ 5~ ~  !P~ !Z !,~ ! .~ !j "D~ "~ " ~ " #E~ #~ # ~ # ${~ $Z~ $ .>~ $ &|~ &~~ & F~ &b '}~ ' ' , ', (~~ (ZK~ ( 2~ ( *;~ *F*~ * "T* ~ *** , -~ -:~ -Z#~ - ~ -G .~ .j ~ .  ~ .R /~ /6~ /v]~ / V`~ / 0 0, 0 ,~ 0:r 1~ 1v 1, 1 ,~ 1~ 2~ 2v~ 2r~ 2 ~ 22 4<~ 4&4&~ 4 &4 &~ 4&nC4& 6 7~ 7N~ 7n#~ 7 ƒ~ 7" 8~ 8N~ 8Na~ 8 ڣ~ 8 9~ 9v 9,~ 9  :~ :v~ :p~ : ~ : ;~ ;~ ;  ~ ; <~ <N~ <u~ < n~ <j =~ =^~ =@ = , =, >~ >^~ >  > , >,@,B,C,D,E,G, @=~ @@~ @ &@ &~ @&n"@& B>~ Br_~ B "~ BҐ C~ CB~ C ~ Cr, D~ D>~ D R~ Db E~ EfE~ E BE ~ EE G~ G&!G&~ G |G ~ G! G !    **** **4444 44@@@@ @@EEEE EEGGGG GGPH0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} @} } } } } } } } } } } } } } } } \}  ,,,,,,, , ,   0   .                w  w  w       w  w  w      w  w  w      w w w       w w w     R    PH0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} !} }  } }  }  } } }  } }  } }  } , @ @ @, @              *~ vC~ ~  r~ ~ j~  ~ |~ B~  ~ ~ f~ bJ   PH0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} 7} }  } }  }  } } }  } }  } }  } }  } }  }  , , @ , @ , , , , , , ,, , , , , , , ,                k                  ~ ~ 7  ,~ N~ R~ @ ,~   | ,~ F  ,~ F ,~ b ,~ b ~ >9~  ,~ "T~  ~ " ,~ *   , , , , , ,~ ~~ ~  , ,~ ~  , ,~ 2~ 2 ~  ,~  ~ ~ B ,~ ~ nC  ~ ƒ ,  ,~ ƒ~ " , ,~ " ~ ~ b~  Y~ ڣ~ ~ J~ ?~   , ,  , ,~ ~ ,~  , ~  ,~   ,~ 2 ,~  , ~ N~   ,~  ~ ~ " ,~   , ,~  n~ n , ,~ j~ j ~ ~ ~  ~ ~ 2A~ ~ V~ n"   PH0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} } }  } }  }  } }  , , @ , , ,         O     *~ z~ ~   3~ v~ ~  ZB   PH0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} 8} }  } }  }  } } }  } }  } }  } , @,,,,, , , ,,,,            k        x        ~ .3~ &~  Y~  ~ x~  | ,~ &~  &~ ~  ~ ~ ~ z~ ¬~ Fi~  ~ Fj ,~ Fj~  ,~   ~ b~ R ~  ~ c ,~ c ~ ~ ~  j~ *~ ~  ~ 2~ ~  N~ ~ ~ v6    PH0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} +} }  } }  }  } } }  } }  } } } }  } ,,,,,,, , , , ,  Q(    S ^  U  V W  V         ~ ~ R ~   $~ J*~ n ,~ # ~ o~ ~  ~  ~  ,~ RE ~ _~ z ~  ~ K~ ^ ,~ :  ~ '~ z ~ ~ K~ ^ ,~ f ~ 8 , , , , ,~ 8 ~ _~ z ~ ~ K~ ^ ,~ :  PH0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} +} }  } }  }  } } }  } }  } }  } }  }  ,,,,,,, , , , Q(    S ^  U  V W  V         ~ :I ~ j~  "~ zr~ d~ %~ m ~ .~ N~   ~ ~ B~ ~  ~ w~ >~  ~ rZ~ d~ 8~ .;  ~ ZU~ >~ ~ rZ~ d~ 8~  ~ " , , , , ,~ " ~ w~ >~ ~ rZ~ d~ 8~ .;  PH 0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} +} }  } }  }  } } }  } }  } }  } }  } ,,,,,,, , , , ,  Q(    S ^  U  V W  V         ~ ޻ ~ ~  U~ r~ A~ ֵ~ 0 ~ J4~ ~  ~ ~ F~ ~ > ~ &~ T~  >~ q~ R[~ z~   ~ ~ ^~ >~ q~ R[~ z~ &4 ~ V$~ jz , , , ,~  ~ &~ T~ >~ q~ R[~ z~   PH00(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} } }  } }  } } } }  } }  } }  } }  } } } !#} $$ } %'} (( } )+} ,, } -/} 00 } 11,1,1 @1,1,  S ^ U$ 'V(0  V     V   V   #$ 'V( +, /0 ~ ~ o~  _~ R ~ ~ z ~  $~  ~ $~ (J*~ , ~ 0K ~ ~ ;~  jM~ #~ ~ F+~ >%~  f~ $!~ (v~ ,~ 0S $'0  #$'(+,/0PH@0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} } }  } }  }  } } }  } }  } }  } }  } }  } "} ## } $ %,$,$ @$,$,$,$, $, %,  W  V#  V     V   V  "# ~ n~ ~  ^ , , ,~ #~ RE~ #: ~ m~ ~  k~ f~ v~ ~ d ~ ~ #BQ  , ,  ,~ . ,~ .~ . ,~ #. p , ,  ,~  ,~ ~  ,~ # F , , ,~ > ,~ >~ > ,~ #> H~ ( ~ ( ~ #(* $j  # "#PHP0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} } }  } }  }  } } }  } }  } }  } }  } }  } "} ## } $&} '' } (*} ++ } ,.} // } 000,0 @0,0, S ^ U# &V'/  V     V   V  "# &V' *+ ./ ~ :I ~ .~  w~ j~ N~ >~ "~  ~ #~ 'zr~ +~ /rZ ~ 7~ ~  ~ Z~ ~ ޓ~ ~ b~ #~ '~ + ~ /Z #&/ "#&'*+./PH`0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} } }  } }  }  } } }  } }  } }  } }  } }  } "} ## } $ $$,$ @$,$,$,$,$,$, W  V#  V     V   V  "# ~ d~ B~  d~ %~ ~ 8~ m~ ~ #.; ~ Zb~ f~  U~ Na~ ~ >~ r~ ~ #Vm  , ,  ,~  ,~ ~  ,~ # p , ,  ,~ fS ,~ fS~ fS ,~ #fS F , ,  ,~ x ,~ x~ x ,~ #x H~ (be~ "~ #"F b  # "#PHp0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} } }  } }  }  } } }  } }  } }  } }  } }  } "} ## } $&} '' } (*} ++ } ,.} // } 000,0,0,0, S ^ U# &V'/  V     V   V  "# &V' *+ ./ ~ ޻ ~ J4~  &~ ~ ~ T~ U~ ~ #>~ 'r~ +~ /q ~ ~ Z~  rd~ ~ l~ H~ f~ Fs~ # ~ 'U~ +RM~ /ڢ #&/ "#&'*+./PH0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} } }  } }  }  } } }  } }  } }  } }  } }  } "} ## } $ %,$,$ @$,$,$,$, $, %,  W  V#  V     V   V  "# ~ A~ F~  R[~ ֵ~ ~ z~ 0~ :~ # ~ T~ ~  K~ u~ F~  Q~ &6~ >~ #b  , ,  ,~  ,~ ~  ,~ # p , ,  ,~  ,~ ~  ,~ # F , , ,~ *E ,~ *E~ *E ,~ #*E H~ "ޣ~ (> ~ #(d $j  # "#PH0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} } }  } }  }  } }  , , , , , , ,       ~ V~ A~  ڿ  ~ g~ ~   ~ ~ ~   ~ ֆ~ *~  r@ V~ :~ .;~   R    PH0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} ,} }  } }  }  } }  , , , , , , , , , ,  =      ~ ~ : ~    ~ ^#~ j~  ^ ~ ~ f~  v ~  ,  , ~  , , ~ "5~ b6~  V~  ~ fS ~  Z      PH0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} .} }  } }  }  } }  , , , , , , , , , ,  =      ~ >~ =~    ~ ~  ~  r ~  ~ ~  J ~ B ~ 2 ~  * ~  , , _~ b~ 2 ~  V~ >~ x~ *EB   PH0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} 1} }  } }  }  } }  , , , , , , , ,  =      ~ j~ u~  ~ ~ j~ u~  ~ ~ ~ v;~   ~ ~ v;~  ~ &~ ~ m*  PH0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} d} }  } }  }  } }  , , , , , , , , , , ,  =      ~ *~ F ~  d ~ ~~ ~  r ~ ~ V~   ~ *v~ چ~  *[ ~ l~ ~  ~ 6~ 2~   ,~ ~ v ~ "&~ "~ "m*  PH0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} } }  } }  } ,,,,,,, , , , ,,,  =    ~ _~   ,~ [ ~ ~  ~ 6~ f V~  Y~  4 ~ s~  ~ ~  ~ ~  V~ RH~ >m"PH0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} } }  } }  } ,,,,, =   ~ 2~   ,~  V~ 2~ PH0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} '} }  } }  } ,,,,,,  =   ~ >k~ m ~ ~  ~ Nj~ >kBPH0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} @} }  } }  } ,,,,,,    ~ ~  ~ Q~ Q ~ ~ ~ #Nj#~ #>k#:PH 0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} $} }  } }  }  } } }  } , @,,,,, , , , ,,,,,             V ~ r~ ~  J~ c ~ b~   ,~   ~ ~ *~  w~   ,~ z  ,~ z ~ b~ R~  R~  ~ ~  , , a~ ~ Z ~ ~  ~ "~  ,~ %  , ,~ |~ |  ,~   ,~  ~ &~ ~  Z~ r ~ ~ ~  ^ , i~ ~ ~  k~ J* PH0 0(   >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} } }  } }  }  } } }  }  @,,,,,, , , , ,,,,          V ~ !~ J~  B~  ~ z~ ~  r/~ n] ~ f~ ~  *~ B a~ f6~ ~  J~ H ~ N ~ ~  /~ BK  ,~   ,~  ~ ~ ~ ~ N ~ ~ N~  , i~ "B~ ~ m~ .s  ~ ~~ D~  ~   ~ ~ z5~  N~ n" PH@0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} 2} }  } }  }  } } }  } }  } , @,,,,, , , , , ,,          V ~ >~ >~  ~ f~  ~ ~ .~  O~ ~ Nx ~ ~   ,~ &~  ~ ~ ~  ~ ~ ֟  ~ ~ r5~  "~ ^ , a~ ~ @~ ʑ~ ~ n  ~ ~ rJ~ ~ ~ 6 ~ ~~  ,~ ~  ~ ~ zt~ Z~ ~ VH ~  F~ e~ ~ ~  i~ ~ _~  F~ >~ 2 PHP0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} 2} }  } }  }  } } }  } }  }  @,,,,,,, , , , ,,,, !       V ~ nr~ N  ,~ j4~ "l  ,~   ,~ ~  "~ v ~ v?  ,~ J~ 2\ ~ >~ J  ,~ ~  a~ ~~   ,~ B~ r ~ ~   ,~ ~ > "~  ~ H  ,~ ~ ^ ~ ~  ,~ ~  ~ ~  ,~ ~ 2 i~ Vw~ b ,~ 7~ ¯  ~ $~ B~  ʑ~ Q~ J  ~ jb~ j^~  F~ ~ n* PH`0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} +} }  } }  }  } } }  } }  } , @,,,,, , , , , ,, # $ %  &  ' V ~ j~ Fg~  >~ z ~ bV (~ ~~ ~  ~ ~ : )~ ~ b~  z~ ~ * *~ z~ >~  ~ ~~ . a~ !~ l~  ~ Z~  (~ f~  , ,~ q )~ F~  ,~ ~  +~  ~  ,~ ~  ~ ~ ~  ,~ 2 *~ ~ r ,~ ~  i~ f~ RO  ,~  ~ s2 PHp0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} } }  } }  } ,,,,, ,   -~ V~  .~ ~ Z V~ ~ >2PH 0(   >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} %} }  } }  } , @,,,, / 0   1~ B ~ f 2~ ~ r 3~ ~  "PH$0(  $>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} } }  } }  }  , @,,,,, , , ,  4 5 F~ R~ b A~ 1~ ' O~ ^a~ .\ 6~ n ~  7~ d~ d ~ br~ / 8~ >~ 2 9~ >~ 2PH(0(  (>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} A} }  } }  }  @,,,, 4 5 :~ d~ d ;~ F2~ F2 <~ ~ . =~ .&~ r&PH,0(  ,>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} !} }  } }  }  ,,,,,,, , , >   ?~ "R~  @~ a~ "] A~ ~  B~ ~ S d~ ;~ < C~  ~ ʯ V~  ~ r :  PH00(  0>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} 2} }  } }  }  , @,,,,, D E   F~ ~~ . G~ 6w~ nj H~ r~  I~ &+~ BPH40(  4>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} &} }  } }  }  } }  , , , , , , , , , , , , , , J       K  K  L     M~ ~ ~  6k  N~ &&~ 6:~   O~ ~ >~   P~ ƥ~ &~ ^ Q ,~ ~  R~ ~ ~ / S~ f , , ~ v ~ ڽ ~ V  .~ Z~ r~   T~  ~ j~  :      PH80(  8>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} } } } } } } } } } }  } }  }  @,,,,  U V      W  X~ ~  i ~  ,~ R W  Y~ ~  z~ ~  Z  [~ ~  z~  ~  \~  ~ ~ #6k#B  PH<0(  <>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} } } } } '} }  } } } }  } }  }  ,,,,,,, ,  @ , , ]  ^ _        ` ~  ~ ~ N  a~ ~  J1~ F`~ k  b~   ,~ B~ 2  c ~  ]~ .u~ D  d ~  ~ 2t~   e~ ~  , ,  f ~ F~ }~ ά  g~ ~ ~ ~  h~ &&~ 6:~ * PH@0(  @>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} } } } } ,} } } } } }  } }  }  , @ @,,,, , , , , i  ^ j        k~ ~  z~ &~   l~ ~  h~ u~ Jl  m~   ,~  ~   n~   ,~  ,  o~   ,~ Z~   p~  ,~  ,  q~ ~ ~ ~ Zd r s~ ~ ~ ~  t~ ~ >~ * PHD0(  D>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} } } } } } } }  } } }  } }  } , @ @,,, u  ^       v  w~ ~  ~ *~~ I r x~   , ,~ X  y~ ~  *~ ~  z~  ƥ~ &~ ^* PH H0(  H>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} } } } } }  } } } } }  } }  } , @,,, {  ^  |      }  ~~   ,~ 6~    ~~   ,~ r~   ,~ ~  2  PH0L0(  L>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} 1} } } } } } }  } } } } } }  ,,,,,,,   ^ _        ~ ~  j  , ,   ~ ~   , ,   ~ ~  ^ , ,   ~ ~  e , , ~  f , ,2  PH@P0(  P>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} +} }  } }  }  } } }  } }  }  , @,,,,, , , ,         W~ ~ F  ,~ ~  ~ 6:~ N~   ~ b~ && ~ >~ u~  q~ ~  ~ &~ ~  f~ ^~ ƥ ~  ,  ,~ ^e , ~ ~  ,~ ~   , ,~ f ,~ f ~ ڽ~ ~ b~ \~ v2 PHPT0(  T>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} +} }  } }  }  } } }  } }  }  , @,,,,, , ,         W~ 6k~   ,~ ~  ~ ~ M~  ~ ƙ~ 6: ~ ~ n~  :~ ~ > ~ ^~ ^~  #~ ~ & ~  ,  ,~ ~  ~ /~  ,~ ~  ~ V~ FJ~ b~ ;~ ڽ2 PH`X0(  X>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} +} }  } }  }  } } }  } }  }   @,,,,,,,        W~ ~ ڥ  ,~ ~ 6k ~ V~ vh~  n~ (~  ~ ~ j~  ^S~ ~  ~ ~ r~  R~ ~ ^ ~  ,~  ~ ~  ~ R ,  ,~ N~ / ~ f~ &~  V ~ z~ V* PHp\0(  \>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} (} }  } }  } ,,,,,,, , , , , ,  =      y~ ~ n z~ 1~  ~ ~ ~ ~ V~  ~ 8~ / ~ ~  ~ F~ b~ ~ ~ ,2PH`0(  `>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} "} }  } }  } ,,,,, =   ~ nn~ &T ~ *~  ~ ~ ,PHd0(  d>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} +} }  } }  }  } }   , , , , , , , =      ~ ,~ ~  s ~ F~ ~   ~ ~ B~  V ~ >~ ~   ~ ~ ,~  "  PHh0(  h>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} &} }  } }  }  } }  , , , , ,, , , , , , ,  =       K  K  ~ ^H~ (~     ~ 2~ :E~ B ~ :~ "~  ~ ng~ >,~ 2 ~ *6~ .~ 2 ~ ~ ~  ~ 6~ ~  b r     PHl0(  l>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} +} }  } }  }  } }  , , , , , , , ,            ~ ~ #~  .%  *~ ~ ~    ,~  ~  2 ~ ~ .~  j ~  ~  ~ # j      PHp0(  p>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} @} }  } }  }  } }  , @ , , , , ,  , , , ,  , , , , , , , , , ,      $  ~ >/~ &~  ^U ~ ~ R~   d~ "z~ F~  2R ~ z~ 2~   ~ ~ v ~  g , , , ~ "z~ F~ 2R ~ z~ 2~  ~ ~ v ~ g , , , ~ "z~ F~  2R ~ 7~ ~  - d~ JA~ b-~  B ~ w~ ~  6 f~ C(~ .~  v ~ ~ *~  J ~ 24~ .~   ~ W~ N~  A ~ =~ ~  6 " PHt0(  t>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} } }  } }  } , @,,,,    ~ g~ . ~ s~  ~ Zb~ ~ ~ S PHx0(  x>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} "} }  }  @,,,,,  ~ : ~ F* ~  ~ ~ "J PH|0(  |>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} } }  } }  }  } }  , , , , , ,  =      ~ rL~ rL~  rL  ~ O~ "~  s~ ~ fo~  & Z     PH0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} $} }  } }  }  } }   , , , , ,      ~ fo~ &~     , ,~  ~ ~ ,~ B~  " ~ ~ fo~  & J    PH0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} 0} }  } }  }  } }  , , , , , , , ,          ~ ~ \~  . ~ +~ ~   ~ ~~ ~    , ,  , ~ ~~ ~   ~ 'g~ '~ '" PH 0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} } }  } } }  } }  , , , , , ,  =      ~  \  \  ~ "o ,  ,~ "i \  \ Z     PH00(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} }  , , , , , , ,       \ \  \  ~ Q \  \   \ \  \  ~ && \  \  =~  \  \       PH@0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} }   , , , , ,       \ \  \  ~ s \  \  ~ && \  \  =~ "o \  \ z     PHP0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} 0}  ,,,,,,,    ~ l ~  ~ &N=& ~ &v;& ~ ::PH`0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} d} } }  ,,,,,,,, , , ,    ~ >8  }   ~ B  ~ : ~    ~   ~  B  PHp0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} }  ,,,,,,, ,    ~ > z~  H~  ~ F ,~ &.& V~ V B PH0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} 6} }  } }  }  } } }  } ,, @,,,, , , , ,,,,,,,,                   ,~ &+  ,~  G , ,  ,~  (  ,~ f  ,~ B D ,~  ,~   ,~  ,~ Y  -~ "i , , , .~ 7 ,  , , ~  ,  , ,  * ,~ v  ,~  3 ,~ 6  ,~ | + ,~   ,~ :B  ,~ 0  ,~ "Z    PH0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} } }  } }  }  } } }  } }  } }  } }  } , @,,,,           V               ~ b~ ~  .1~ ~ ~ ~  ~ ~ J~  ~ ~ ~ ҽ~ ~ &~ N~  0~ ~ ~ ~ үB PH0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} } }  } }  }  } } }  } }  } }  } }  }  @,,,,          V           ~ >~ Q~  :.~ j~ Z~ ~  ~ ~ ~  ~ j~ ~ v~ nj~ ~ fO~  ,~ ~ j~ \~ 2: PH0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} } }  } }  }  } } }  } }  } }  } }  }  @,,,,          V           ~ =~ B~  M~ "~ b~ ~ a ~ ~ ~  ~ ~~ ~ \~ L~ 26~ ~  L~ >!~ r~ (~ : PH0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} } }  } }  }  } } }  } }  } }  }  ,,,,,,, , , ,  @           ~ ~ ~  ƪ~ V~ _~ b r~ jm~ "K~  h~ nq~ ޫ~ z ! , ,~  ~* , ,~ b "~ j~ j~  Z~  ,~  #~ m~ R~ NK ,~ 2z~ “ $~  ~  ,~ .~  , %~ ~ J ,~ ~ Z ,J   PH0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} } }  } }  }  } } }  } }  } }  }  ,,,,,,,, , & '         ~ >~ Z#~   ~ +~ ~  r~ ~ ~  ~ R~ ~ z ! , ,~   , ,~ 6 "~ ~ ~  ~ >~ *~ ^ #~ ~ ~  ~ 6 ~ B~ Z $~ ~ >  ,~ n~  , %~ ~  ,~ ~  ,B  PH0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} } }  } }  }  } } }  } }  } }  } }  } }  } "} ## } $$,$,$ @$,$,$, (   # ) *  +  , * + , * "+# -~  &~ 0~  j~ >i~ y~ X~ Δ~ ~ # .~ /~ 2~  ,~ ~ ~ ¼~  ~ (~ # V~ U~ c~  JH~ - ~ D ~  ~ ~~ ~ #6j  # "#PH0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} $} }  } }  }  } } }  } }  } }  } }  }  ,, @,,,, , , / 8 , 0  1  2 3 4 5 6         *~ Ά ~ Nq~  d~ ~ ~ =~ r ~ 6~ 6~  6 , , , , ~ ~ o~  ~ s~ VS~ ~  +~  ~  ~  , , , ,~ 0~ ~ ޸ ~ {~ B~ v~ d  PH0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} $} }  } }  }  } } }  } }  } }  } }  }  , @,,,,,, 8 , 0  1  2 3 4 5 6         *~ ~~ *b&~  ~ ~ H~ >~  ~ ~ ~   , , , , ~ >~ Nj~  ~ ~ i~ 5~ bN +~ :B~ :B~  .~  , , ,~ "~ >/~  V ~ R~ ~ G~ Wz  PH0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} } }  } }  }  } }  , , , , ,       7~ 4~ ~   8~ ~ "}%~  # 9~ %~ %~  %" PH 0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} -} }  } }  }  } }  , @ , , , , :       ;~ ;~ :~  2 <~ ~ ^~  z =~ ~ .~  &*  PH00(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} } }  } }  }  , @,,,, , , >    +~ ~ J ?~ .o~  +~  ~ :B .~  ~ . - ,~ "PH@0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} } }  } }  }  } }  , , , , , , @ A      ~ ~ ~  z  B , ,~   C~ ~ ~   ~ R~ ~   R    PHP0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} } }  } }  }  } }   , , , , , , D      ~ ~ G~    B ,~   , E~ p~ ~   F~ ~  ~  B ~ .o~ ~  G J    PH`0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} } }  } }  } , @,,,, G    H~ ~4~ ( I~ ~ ~ ^R~ v*BPHp0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} >} } } +,,,,,,, , , , , ,,,,,,,,,,,,,,,,,,, J K L M N O P     Q  R  S  T  U  V W V  X  Y Z [  \  ]  ^  _  `  a  b  c    d e f  g  h i j i ,!,",#,$,%,&,',(,),*, k l !m ! "n " #o # $p $ %q % &r & 's ' (t ( )u )v *w * PH0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} } } } ,,,, x y z { | } ~ PH0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} } } } , @,, x y  {  }  PH0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} } } ,,,,,  z { | } ~  PH0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?" d,, ` `? ` `?U} } } , @,,,   {  }   PH0(  >@<dgg   FMicrosoft Excel 97-TabelleBiff8Oh+'0|8 @ L X d p0@@@^@^՜.+,D՜.+,\ H AppVersion DocSecurityHyperlinksChangedLinksUpToDate ScaleCrop ShareDoc12.0000 Root EntryFWorkbookCompObjIOle SummaryInformation(DocumentSummaryInformation8h